Advanced drug delivery for central nervous system (A. des Rieux)

Bruxelles Woluwe

We develop nanomedicines for the central nervous system (CNS) repair. Our objective is to stimulate brain repair by either recruiting neural stem cells (NSC) at the site of injury, stimulating their differentiation and/or resolving inflammation.

Regarding NSC recruitment, we developed SDF-1 PLGA nanoparticles that, once implanted at the site of a traumatic brain injury, were able to recruit NSC at the damaged area (L. Zamproni, Universidade Federal de Sao Paulo, BR).

We also showed, in collaboration with P. Saulnier and J. Eyer (Université d’Angers, FR) that by modifying the surface of lipidic nanocapsules (LNC) with a peptide (NFL), we were able to specifically target NSC of the brain and to stimulate their differentiation toward the oligodendrocyte lineage (Thesis of D. Carradori) (Figure 1).

Our ongoing projects focus on new nanomedicines aiming at stimulating the differentiation of oligodendrocyte progenitor cells and resolving inflammation in the brain, more particularly in the scope of multiple sclerosis.

Figure 1: Targeted drug delivery for CNS repair.